<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) following treatment with chemotherapy or irradiation are termed 'secondary' <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical observations suggest a worse prognosis for secondary than for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but differences in survival have not been studied in a general population sample </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) program to describe survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients according to previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>Our study included 3,938 MDS cases diagnosed in 2001-2004 and reported by registries which have participated in SEER since the 1970s </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis (26% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases) was associated with 13% increased risk of <z:hpo ids='HP_0011420'>death</z:hpo> from any cause among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases (hazard ratio [HR]=1.13, 95% confidence interval [CI]: 1.02-1.25) </plain></SENT>
<SENT sid="5" pm="."><plain>Radiation treatment for a previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was associated with 52% increased risk of <z:hpo ids='HP_0011420'>death</z:hpo> (95% CI: 1.15-2.02) </plain></SENT>
<SENT sid="6" pm="."><plain>Shortened survival was most pronounced if the latency between the previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was less than five years, including <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> diagnosed in the year preceding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (HR = 3.43, 95% CI: 1.93-6.10) and lymphohematopoietic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> 1-5 years before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (HR = 2.11; 95% CI: 1.33-3.36) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our results confirm a more severe prognosis for <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> than for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, associated with certain types and treatments of previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>